Gaggin, Hanna K.
Belcher, Arianna M.
Gandhi, Parul U.
Ibrahim, Nasrien E.
Januzzi, James L. Jr
Article History
Received: 19 May 2016
Accepted: 18 August 2016
First Online: 8 September 2016
Compliance with Ethical Standard
:
: Assays for IL-6, VEGF, and TNF-α were performed by Singulex, Inc. The sponsor had no role in design, data collection, analysis, manuscript preparation, interpretation, or decision to submit the manuscript for publication. Dr. Ibrahim is supported by the Dennis and Marilyn Barry Cardiology Fellowship. Dr. Gaggin is supported in part by the Ruth and James Clark Fund for Cardiac Research Innovation, and Dr. Januzzi is supported in part by the Hutter Family Professorship in Cardiology.
: Dr. Gaggin reports the following disclosures: (1) Roche Diagnostics: research grant, consultancy; (2) Portola: research grant; (3) Amgen: consultancy; (4) American Regent: consultancy; (5) Boston Heart Diagnostics: consultancy; (6) Critical Diagnostics: consultancy; and (7) EchoSense: clinical endpoint committee. Dr. Januzzi reports the following disclosures: (1) Roche Diagnostics: research grants, consultancy; (2) Siemens Diagnostics: research grants; (3) Prevencio: research grants; (4) Singulex: research grants; (5) Critical Diagnostics: consultancy; (6) Sphingotec: consultancy; (7) Philips: consultancy; (8) Cardiorentis: consultancy; (9) Novartis: clinical endpoints committee, consultancy; (10) Boeringer-Ingelheim: clinical endpoints committee, consultancy; and (11) Amgen: data monitoring committee. None of the other authors has disclosures.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.